benserazide


Also found in: Wikipedia.

benserazide

 [ben-ser´ah-zīd]
an inhibitor of the decarboxylation of peripheral levodopa to dopamine, having actions similar to those of carbidopa. When given with levodopa, benserazide produces higher brain concentrations of dopamine with lower doses of levodopa, thus lessening the side effects seen with higher doses. It is used orally, in conjunction with levodopa, as an antiparkinsonian agent.

ben·ser·a·zide

(ben-ser'ă-zīd),
An l-aromatic amino acid decarboxylase (dopa decarboxylase) inhibitor resembling carbidopa in action; given in combination with levodopa as an antiparkinsonian regimen. The benserazide prevents peripheral destruction of levodopa and thus reduces cardiovascular side effects of treatment.

benserazide

A dopamine precursor drug given in conjunction with LEVODOPA in the treatment of PARKINSON'S DISEASE to prevent the breakdown of levodopa in the body. A brand name is Madopar.
References in periodicals archive ?
Levodopa benserazide drug tablet (capsule) 200 mg 50 mg 336 410 units, 155 085.
(23) Nutritional requirements for B-6 (pyridoxine or pyridoxal 5'-phosphate) may be increased by the use of certain medications (oral contraceptives, isoniazid, hydralazine, benserazide, penicillamine, phenelzine, cycloserine, thiamphenicol carbidopa, etc.).
For L-dopa treatment, 25 mg/kg L-dopa (L-dopa methyl ester hydrochloride-Sigma-Aldrich, USA) was dissolved in saline together with 6.25 mg/kg benserazide (benserazide hydrochloride-Sigma-Aldrich, USA) as a peripheral dopa-decarboxylase inhibitor.
She was using 100 mg L-Dopa+25 mg benserazide, 0.25 mg pramipexole, 25 mg carvedilol, rasagiline, 150 mg irbesartan, 12.5 mg hydrochlorothiazide and 100 mg acetylsalicylic acid tablets.
Animals received the intraperitoneal administration with saline or 25 mg/kg of levodopa methyl ester mixed with 6.25 mg/kg of benserazide tablets (Roche Diagnostics, Penzberg, Germany) dissolved in sterile saline once daily at 15:00 for another 21 consecutive days.
Variable Patient Beta P value percentage value Total patients 76 (100%) / / Levodopa and Benserazide 54 (71.1%) -0.169 0.143 Hydrochloride Tablet Carbidopa and Levodopa-CR 8 (10.5%) -0.106 0.362 Tablet Levodopa Tablet 1 (1.3%) 0.042 0.717 Piribedil-SR Tablet 27 (35.5%) 0.759 0.450 Pramipexole Dihydrochloride Tablet 15 (19.7%) -0.042 0.720 PD, Parkinson's disease; Beta value, adjusted regression coefficient; CR, controlled release; SR, sustained release.
The most effective treatment for PD involves DA replacement therapy, made by the administration of its precursor 3,4-dihydroxy-L-phenylalanine (L-DOPA) associated with dopa-decarboxylase inhibitors (benserazide or carbidopa).
PD rats with successful modeling were produced by intraperitoneally injecting LD (10mg/kg) and benserazide (2.5mg/mL, dissolved in sterile normal saline with 0.05% ethanol and 0.05% ascorbic acid) twice a day (10 mg/kg per day) for 4 weeks.
The majority of Parkinson's Disease patients receive Levodopa, however when administered orally, the drug, combined with a decarboxylase inhibitor (carbidopa or benserazide), demonstrates a short clearance half-life and low bioavailability that contribute to motor complications in Parkinson's disease patients.
His previous medical history included: (a) a 30-year history of hypertension that had been controlled at about 140/90 mmHg with amlodipine 5mg/d; (b) a 4-year history of type II diabetes treated with 50 mg acarbose tid (keeping the blood sugar to about 7.8mmol/L); (c) a 2-year history of Parkinson's disease treated with 125mg benserazide tid; and (d) a 2-month history of visual hallucinations that were being controlled with 1.25 mg olanzapine bid.